Astrazeneca (AZN) EBIT Margin (2009 - 2026)

Astrazeneca's EBIT Margin history runs 18 years deep, the most recent figure standing at 5514.29% for Q1 2026.

• In Q1 2026, EBIT Margin rose 54942.0% year-over-year to 5514.29%; the TTM figure through Mar 2026 stood at 14034.31% (up 1292486.0% YoY), while the FY2025 annual figure was 23.4%, down 106035.0% from the prior year.
• EBIT Margin was 5514.29% for Q1 2026 at Astrazeneca, down from 49633.33% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 68650.0% in Q2 2024 to a low of 249.82% in Q4 2024.
• Historically, EBIT Margin has averaged 14635.22% across 5 years, with a median of 4964.86% in 2025.
• The sharpest annual moves came in 2024 and 2025: EBIT Margin surged 6737746 bps in 2024, then tumbled 2480000 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 692.41% in 2022, then slumped by 36 bps to 445.49% in 2023, then sank by 44 bps to 249.82% in 2024, then soared by 19768 bps to 49633.33% in 2025, then tumbled by 89 bps to 5514.29% in 2026.
• The last three EBIT Margin figures came in at 5514.29% (Q1 2026), 49633.33% (Q4 2025), and 32572.73% (Q3 2025), per Business Quant data.